The Numbers That Matter: In the landmark SURMOUNT-5 trial published in the New England Journal of Medicine in May 2025, participants taking tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% with semaglutide
GLP-1RA, glucagon-like peptide-1 receptor agonist
States that do opt to cover various weight loss treatments, including medications, nutrition programs and bariatric surgery, almost invariably deploy restrictive eligibility requirements around things like body mass indices and the presence of co-morbidities, along with the use of prior authorization and step edits
Ozempic is typically prescribed to those who have not achieved sufficient weight loss through diet and exercise alone
Familial hypercholesterolemia, FH for short, is not as uncommon as we thought
35, 36, 68 In contrast, our results differ from activation of ET-1 receptors on PSCs, which does not stimulate proliferation